The Remission Monitoring hand held device and test strip will look similar to this Xprecia PrimeTM product which Universal Biosensors sells across Europe
The Victorian Cancer Biobank (VCB) is supporting another ground-breaking innovation in Victoria for easy point-ofcare monitoring of cancer reoccurrence. Universal Biosensors, a Victorian based company, has obtained biospecimens from VCB for their international development clinical study. Their study aims to develop a handheld portable cancer biosensor for T and Tn Antigen using a “finger prick” blood test for measuring patient cancer remission and reoccurrence. It is estimated that 78 million people globally are currently in cancer remission, and the Cancer Biomarker biosensor test could potentially revolutionise cancer monitoring which is currently only available through clinic or hospital-based imaging and blood tests. Ultimately, this technology advancement may one day allow us to manage cancer reoccurrence as easily as monitoring blood sugar levels for diabetic patients.
The developmental stage study has assessed the performance of the test in a cohort of 346 patients across multiple cancer types, including colorectal, prostate and breast. The test is showing improved sensitivity and specificity when compared against common cancer biomarkers being used currently such as Carcinogenic Antigen (CEA) and prostate-specific antigen (PSA).
VCB has significantly contributed specimens to about a third of the cohort of this initial study and is expecting to contribute more towards further development of the test.